Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) Stock Price, Analysis & Data
| Precio de compra | 63.95 |
| Capitalización de mercado | 130.39B |
| Ingresos (TTM) | 49.19B |
| Beneficio neto (TTM) | 9.28B |
| Beta | 0.23 |
| EPS (TTM) | 4.54 |
| Ratio PER (TTM) | 14.25 |
| Adelante PE | 9.74 |
| P/B (TTM) | 5.84 |
| P/S (TTM) | 2.65 |
| Earnings Date | Oct 29, 2026 |
| Precio de venta | 64.04 |
| Volumen | 7,528,229 |
| Volumen medio (20D) | 12,472,452 |
| Abierto | 64.13 |
| Anterior Cerrar | 64.65 |
| Rango del día | 63.35 - 64.33 |
| Rango de 52 semanas | 42.52 - 68.10 |
| analista | Buy |
| Precio objetivo | 68 (6.53%) |
| Dividendos | $2.52 (3.9%) |
| Fecha ex dividendo | 2 jul 2026 |
Acerca de BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy f...
Desempeño financiero
En 2025, los ingresos de Bristol-Myers Squibb fueron 48.2B, una disminución de -0.22% en comparación con 48.3B del año anterior. Las ganancias fueron 7.05B, una disminución de -178.83%.
Estados financierosPronóstico del analista
Según las calificaciones de los analistas de 24, la calificación promedio de las acciones de BMY es "Buy". El pronóstico del precio de las acciones a 12 meses es 68, que es Potencial alcista de 6.53% del último precio.
Previsiones bursátilesSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
15 minutos hace · Simply Wall St.
Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval LandsBristol-Myers Squibb stock has delivered a 38.1% gain over the past year, while valuation work using a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples both currently point t...
10 horas hace · Simply Wall St.
Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced?Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, introducing the first approved CELMoD therapy in this dis...